Johns Hopkins University
Therapeutic cancer vaccines amplify tumor-specific regulatory T cells
Published in Oncology Business Week, March 12th, 2006
According to researchers in the United States, "The fate of tumor-specific CD4+ T cells is central to the outcome of the host immune response to cancer. We show that tumor antigen recognition by a subset of CD4+ T cells led to their differentiation into cells capable of suppressing naive and Th1 effector cells."
"Such tumor-induced regulatory T cells (TMTregs) arose both from precommitted 'natural' regulatory T cells and CD4+CD25-GITRlow precursors," said Gang Zhou and colleagues at Johns Hopkins University. "Once induced, TMTregs were capable of maintaining suppressor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- AEterna Zentaris, Inc.
Cancer drug developer's strategic shareholder exercises right to convert loan - Access Pharmaceuticals, Inc.
Tumor therapy developer completes $5M convertible offering - Biopro Baden-Wuerttemberg GmbH
German software founder invests EUR 22 million in Tuebingen cancer-focused biotech company - Breast Cancer
Alliance publishes international breast health guidelines for developing countries - Bulgarian Academy of Sciences, Sofia
New findings in the area of prostate cancer vaccines described - Calando Pharmaceuticals, Inc.
Alliance forged with U.S. National Cancer Institute to develop RNAi therapeutics - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
